Exploring Molecular Pathways Underlying Epilepsy Development in Intellectual Disability
Çağatay Günay1, Leman Binokay2, Gökhan Karakülah2
1Department of Pediatric Neurology, Siirt Training and Research Hospital, Siirt, Turkey.
Neuropediatrics
|December 11, 2025
Summary
Intellectual disability (ID) and epilepsy share molecular pathways, with 75% of ID genes linked to epilepsy. Key genes and pathways offer potential therapeutic targets for comorbid conditions.
Area of Science:
- Genetics and Molecular Biology
- Neuroscience
- Developmental Biology
Background:
- Intellectual disability (ID) and epilepsy frequently co-occur, but the underlying molecular mechanisms remain largely unknown.
- Understanding shared genetic pathways is crucial for developing targeted therapies for individuals with both conditions.
Purpose of the Study:
- To investigate the molecular pathways associated with epilepsy development in the context of intellectual disability.
- To identify shared genetic mechanisms and potential therapeutic targets linking ID and epilepsy.
Main Methods:
- Extracted ID-related genes from the SysNDD database.
- Performed gene set overrepresentation analysis using KEGG, GO, and DO terms to assess associations with epilepsy pathways.
- Classified and analyzed enriched pathways and specific gene involvement.
Main Results:
- Approximately 75% of ID-related genes showed association with epilepsy pathways.
- Enriched pathways included neurotransmitter signaling, ion channel regulation, and metabolic processes ('nicotine addiction', 'thermogenesis').
- Key genes (e.g., GRIN2A, CACNA1A, PIGB) implicated in multiple pathways suggest significant overlap in mechanisms.
Conclusions:
- Significant overlap exists between molecular pathways in ID and epilepsy, particularly in neurotransmitter and ion channel functions.
- Identified genes and pathways provide potential targets for therapeutic interventions.
- Further research is warranted to elucidate the causal genetic underpinnings of epilepsy in individuals with ID.
Related Concept Videos
Epilepsy and Seizures: Overview
1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K
Intellectual Disability
595
Intellectual disability (ID) is a neurodevelopmental condition characterized by deficits in intellectual and adaptive functioning that manifest during the developmental period. This condition encompasses challenges in reasoning, memory, problem-solving, and learning, accompanied by impairments in everyday life skills, such as communication, self-care, and social interactions. Intellectual disability affects approximately 1% of the population in the United States, impacting an estimated 5...
595
Antiepileptic Drugs: Glutamate Antagonists
857
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
857
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
790
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
790
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
1.8K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
1.8K


